Company intelligence / Profile preview

Placental Histotherapy Center

Havana, Cuba

Ownership: Private
Employees: ~170
Development stage: Other

Overview

The center's therapies, mainly derived from human placenta extracts, are marketed for vitiligo, psoriasis, and alopecia, claiming high efficacy rates, minimal side effects, and use in over 80 countries. For example, 84% response rates in vitiligo and 78% in psoriasis have been reported, with ongoing research and new programs under clinical evaluation including controlled clinical trials for lead products like Melagenina Plus[1][2][7].

Therapeutic areas: HematologyEndocrinologyDermatology
Modalities: Biologic
Industry: Biotech

Partnerships

Heber Biotec (international marketing partner)ENSUFARMA (national distribution partner)

Beyond the preview

Go deeper on Placental Histotherapy Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Placental Histotherapy Center.

Explore the full profile